Methylphenidate vs Saffron for mood
Short answer: For mood, more users report improvement with Saffron — 92% of 165 reports, versus 41% of 66 for Methylphenidate.
Methylphenidate has 383 meta-analyses and 1,123 randomized trials on PubMed; Saffron has 88 and 119.
Based on 567 reports about Methylphenidate and 421 about Saffron. Not medical advice.
| Methylphenidate Medication | Saffron Supplement | |
|---|---|---|
| Users say it helped | 39%helped352 reports · high confidence | 62%helped223 reports · high confidence |
| Verdict | Mixed | Mostly positive |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 383 / 1,123 | 88 / 119 |
| Mainly used for | ||
| Focus % reporting improvement | 83% (262) | 79% (38) |
| Mood % reporting improvement | 41% (66) | 92% (165) |
| Anxiety % reporting improvement | 29% (48) | 81% (84) |
| Energy % reporting improvement | 61% (67) | 81% (21) |
| Sleep % reporting improvement | 29% (21) | 72% (18) |
| Common side effects | anxiety, jitteriness, insomnia, fatigue | headache, appetite suppression, insomnia, vivid dreams |
| Typical dose reported | Not listed | 30 mg |
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“I tried both ritalin worked way better in me like way better.”
Saffron demonstrates promise in improving ADHD symptoms, with an acceptable safety profile. Future well-designed multicentral studies are suggested.
J Atten Disord, 2024 ↗“I just sneak some into whatever soup we are having. I honestly think it has made a huge difference.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate